EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer

Dapeng Wu, Juanjuan Cui, Wenjing Zhum, Tao Qin, Hanlin Xu

ONCOLOGY · 12.03.2026 · 40 (2) · 123

DOI: 10.46883/2026.25921065 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift ONCOLOGY, online erschienen am 20.03.2026. Verfasst von Dapeng Wu und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Immunotherapy combined with chemotherapy is a standard treatment for advanced non–small cell lung cancer (NSCLC). However, the comparative efficacy and safety of cost-efficient modified PD-1 inhibitors remain incompletely characterized. This study aimed to determine the optimal choice for the 3 most commonly used modified PD-1 inhibitors— tislelizumab, sintilimab, and camrelizumab—combined with chemotherapy in locally advanced or metastatic NSCLC. Materials and methods: We conducted a retrospective study of patients with NSCLC who received chemotherapy plus 1 of the modified PD-1 inhibitors. The primary objective was to compare survival and therapeutic responses across groups. The secondary objective was to analyze adverse events in each group.

Results

No significant differences were observed in median progression-free survival (PFS) or overall survival across the 3 groups. However, PD-L1–positive patients (tumor proportion score ≥ 1%) demonstrated significantly prolonged PFS with tislelizumab (P = .038) and sintilimab (P = .031) vs camrelizumab. The incidence of immune-related adverse events did not differ statistically across treatments.

Conclusion

Although survival outcomes were comparable among the 3 PD-1 inhibitors in the overall cohort, tislelizumab and sintilimab showed superior PFS in PD-L1–positive subgroups, suggesting biomarker-driven therapeutic selection. These findings underscore the importance of PD-L1 status in optimizing immunotherapy regimens for advanced NSCLC, offering clinical insights for personalized treatment strategies. Keywords: NSCLC, tislelizumab, sintilimab, camrelizumab, PD-L1

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsHumansFemaleMaleAntibodies, Monoclonal, HumanizedRetrospective StudiesMiddle AgedAgedProgrammed Cell Death 1 ReceptorProgression-Free SurvivalAdult

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorscamrelizumabsintilimabtislelizumabProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Zitieren

APA

Wu, D., Cui, J., Zhum, W., Qin, T., & Xu, H. (2026). Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer. ONCOLOGY, 40(2), 123. https://doi.org/10.46883/2026.25921065

Vancouver

Wu D, Cui J, Zhum W, Qin T, Xu H. Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer. ONCOLOGY. 2026;40(2):123. doi:10.46883/2026.25921065

BibTeX
@article{Wu2026,
  author = {Wu, Dapeng and Cui, Juanjuan and Zhum, Wenjing and Qin, Tao and Xu, Hanlin},
  title = {Comparison of the 3 Most Commonly Used Modified PD-1 Inhibitors Plus Chemotherapy in Inoperable Wild-Type Non-Small Cell Lung Cancer},
  journal = {ONCOLOGY},
  year = {2026},
  volume = {40},
  number = {2},
  pages = {123},
  doi = {10.46883/2026.25921065}
}
Kostenlos starten →